123 patients (FAS) had completed one year of (neo)adjuvant therapy with T. Prior neoadjuvant chemo-immunotherapy treatment of HER2+ BC was administered in 54 patients (42.9%). The gene discussed is ERBB2; the disease is breast cancer.